Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

[1]  Gregory M. Chen,et al.  Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.

[2]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[3]  M. Kersten,et al.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[4]  S. Berger,et al.  An NK-like CAR T cell transition in CAR T cell dysfunction , 2021, Cell.

[5]  N. Taylor,et al.  Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy , 2021, Cancers.

[6]  K. Davis,et al.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.

[7]  K. Kong,et al.  Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[9]  D. Miklos,et al.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[10]  Michael R. Green,et al.  Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.

[11]  Jinyan Liu,et al.  Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy , 2020, Journal for ImmunoTherapy of Cancer.

[12]  P. Hari,et al.  Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial , 2020, Nature Medicine.

[13]  Howard Y. Chang,et al.  Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies , 2020, Cell.

[14]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[15]  J. Rasko,et al.  The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma , 2020, Signal Transduction and Targeted Therapy.

[16]  Matthew J. Frigault,et al.  Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Vose,et al.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Myklebust,et al.  Tuning the Antigen Density Requirement for CAR T Cell Activity. , 2020, Cancer discovery.

[19]  Mark R. Enstrom,et al.  Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy , 2020, Nature Communications.

[20]  Howard Y. Chang,et al.  c-Jun overexpression in CAR T cells induces exhaustion resistance , 2019, Nature.

[21]  M. Perales,et al.  CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma. , 2019, Blood.

[22]  C. Turtle,et al.  Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy , 2019, Bone Marrow Transplantation.

[23]  M. Delorenzi,et al.  TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection , 2019, Nature.

[24]  Yong Liu,et al.  TOX is a critical regulator of tumour-specific T cell differentiation , 2019, Nature.

[25]  S. Berger,et al.  TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion , 2019, Nature.

[26]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[27]  P. Hogan,et al.  TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion , 2019, Proceedings of the National Academy of Sciences.

[28]  R. Satija,et al.  Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression , 2019, Genome Biology.

[29]  A. Yoshimura,et al.  Nr4a transcription factors limit CAR T cell function in solid tumors , 2019, Nature.

[30]  C. Mackall,et al.  CAR T cell therapy: inroads to response and resistance , 2019, Nature Reviews Immunology.

[31]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[32]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[34]  Alaina Kaiser,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[35]  C. Mackall,et al.  Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.

[36]  L. Deangelis,et al.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[37]  H. D. Liggitt,et al.  Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. , 2018, Cancer discovery.

[38]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[39]  Evan W. Newell,et al.  Epigenomic‐Guided Mass Cytometry Profiling Reveals Disease‐Specific Features of Exhausted CD8 T Cells , 2018, Immunity.

[40]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[41]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[42]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[43]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[44]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[45]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  H. Swerdlow,et al.  Large-scale simultaneous measurement of epitopes and transcriptomes in single cells , 2017, Nature Methods.

[47]  John C. Marioni,et al.  Testing for differential abundance in mass cytometry data , 2017, Nature Methods.

[48]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[49]  Katy Rezvani,et al.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. , 2016, The Journal of clinical investigation.

[50]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[51]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[52]  A. Larbi,et al.  CD57 in human natural killer cells and T-lymphocytes , 2016, Cancer Immunology, Immunotherapy.

[53]  T. Holderried,et al.  Stable inhibitory activity of regulatory T cells requires the transcription factor Helios , 2015, Science.

[54]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[55]  R. Kaplan,et al.  4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.

[56]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[57]  Eli R. Zunder,et al.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[58]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[60]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[61]  Harjeet Singh,et al.  Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials , 2013, PloS one.

[62]  Erin F. Simonds,et al.  A platinum‐based covalent viability reagent for single‐cell mass cytometry , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[63]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[64]  H. Pircher,et al.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. , 2010, Blood.

[65]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[66]  Robert Gentleman,et al.  flowCore: a Bioconductor package for high throughput flow cytometry , 2009, BMC Bioinformatics.

[67]  Alf Hamann,et al.  Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? , 2009, Nature Reviews Immunology.

[68]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[69]  L. Picker,et al.  Distribution of human CMV‐specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms , 1999, European journal of immunology.

[70]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[71]  F. Preijers,et al.  Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection , 1995, British journal of haematology.

[72]  C. Balch,et al.  A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). , 1981, Journal of immunology.